Furthermore, a study by Telli et al. has shown that the [18F]FDG-derived tumor burden is an independent prognostic factor for overall survival, even among patients eligible for PSMA-based radioligand therapy, regardless of treatment received. This evidence concerns the gene FOLH1 and neoplasm.